Literature DB >> 20491048

Focal posterior pole viral retinitis.

Dicle Hazirolan1, Gulten Sungur, Necati Demir, Remzi Kasim, Sunay Duman.   

Abstract

PURPOSE: To describe the clinical features of an atypical form of viral retinitis in immunocompetent patients.
METHODS: This was a retrospective noncomparative case series. The charts of 8 patients diagnosed with and treated for focal posterior viral retinitis were reviewed. Clinical and demographic features were evaluated. All the patients had extensive laboratory tests, fundus fluorescein angiography, optical coherence tomography of macula, and polymerase chain reaction of vitreous.
RESULTS: All the patients were referred to our Uveitis Service from other hospitals, as their uveitis symptoms deteriorated in spite of treatment. The mean age of 4 male and 4 female patients was 32.1 years (range, 22-42 years). The mean follow-up period was 10 months (range, 6-18 months). All of the patients had unilateral disease. Polymerase chain reaction analysis of vitreous specimen was positive for herpes simplex virus-1 in 5 patients and varicella zoster virus in 3 patients. Retinitis resolved after systemic acyclovir treatment in all patients.
CONCLUSIONS: Viral etiology must be borne in mind in the differential diagnosis of atypical retinitis. It can be a milder form of viral retinitis like focal viral retinitis, as mentioned in this study. The prognosis of this disease is better than the other forms of necrotizing retinopathies involving a larger area of retina.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20491048     DOI: 10.1177/112067211002000518

Source DB:  PubMed          Journal:  Eur J Ophthalmol        ISSN: 1120-6721            Impact factor:   2.597


  1 in total

1.  Role of multicolour imaging in post-fever retinitis involving posterior pole.

Authors:  Srinivasan Sanjay; Nikitha Gurram Reddy; Ankush Kawali; Padmamalini Mahendradas; Ram Snehith Pulipaka; Rohit Shetty; Naresh Kumar Yadav; Ramesh Venkatesh
Journal:  Int Ophthalmol       Date:  2021-07-14       Impact factor: 2.031

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.